Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.

BE BOLD Week 24 data show sustained numerical advantages in joint responses with bimekizumab versus risankizumab in active psoriatic arthritis.

Doral Fredericks, PharmD, MBA, discusses how life stages, mental health, and reproductive concerns can shape dermatologic care for women.

The approval expands the IL-23 inhibitor’s indications beyond moderate-to-severe plaque psoriasis to include adults with active psoriatic arthritis.

Updated SKYRIZI labeling allows clinicians to use clinical judgment when determining the need for TB evaluation before treatment.

Experts outline how to recognize undertreated psoriasis, assess incomplete response, and make individualized decisions when escalating therapy.

ORKA-001 achieved PASI 100 in 61% of high-dose patients at week 16 in the phase 2b EVERLAST-B trial of moderate-to-severe psoriasis.

A pediatric dermatologist explains how CALM count, size, age, and associated findings separate benign spots from neurofibromatosis type 1 and its mimics.